NCT03141463 is a Phase 1 clinical trial of Vvax001 therapeutic cancer vaccine in CIN 2/3, sponsored by University Medical Center Groningen.

Who is sponsoring NCT03141463?

NCT03141463 is sponsored by University Medical Center Groningen.

What drugs are being tested in NCT03141463?

Interventions in NCT03141463: Vvax001 therapeutic cancer vaccine.

What condition does NCT03141463 study?

NCT03141463 studies CIN 2/3, Cervical Cancer.

Is NCT03141463 still recruiting?

NCT03141463 is currently completed. Last updated 3 May 2018.

Last reviewed 2018-05-03 · How we verify

NCT03141463

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Vvax001 Cancer Vaccine in (Pre) Malignant Cervical Lesions

Completed Phase 1 Last updated 3 May 2018

What this trial tests

Phase 1 trial testing Vvax001 therapeutic cancer vaccine in CIN 2/3 in 12 participants. Completed in 28 November 2017.

Timeline

13 January 2017

Primary endpoint
28 November 2017

28 November 2017

Quick facts

Lead sponsor	University Medical Center Groningen
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	12
Start date	13 January 2017
Primary completion	28 November 2017
Estimated completion	28 November 2017
Sites	1 location across Netherlands

Drugs / interventions tested

Vvax001 therapeutic cancer vaccine — full drug profile →

Conditions studied

CIN 2/3 — all drugs for CIN 2/3 →
Cervical Cancer — all drugs for Cervical Cancer →

Sponsor

University Medical Center Groningen

Who can join

18 and older, female only, with CIN 2/3 or Cervical Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Immune modulating effects and safety of Vvax001; different dosages will be tested in patients with a history of (pre) malignant cervical lesions.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Cervical Cancer Immunotherapy: Facts and Hopes.
Ferrall L, Lin KY, Roden RBS, Hung CF, et al · · 2021 · cited 255× · PMID 33888488 · DOI 10.1158/1078-0432.ccr-20-2833
Therapeutic vaccines for high-risk HPV-associated diseases.
Chabeda A, Yanez RJR, Lamprecht R, Meyers AE, et al · · 2018 · cited 148× · PMID 29277575 · DOI 10.1016/j.pvr.2017.12.006
Therapeutic Vaccines for HPV-Associated Malignancies.
Smalley Rumfield C, Roller N, Pellom ST, Schlom J, et al · · 2020 · cited 87× · PMID 33117742 · DOI 10.2147/itt.s273327
Next generation self-replicating RNA vectors for vaccines and immunotherapies.
Aliahmad P, Miyake-Stoner SJ, Geall AJ, Wang NS. · · 2023 · cited 34× · PMID 35194198 · DOI 10.1038/s41417-022-00435-8
Scope and challenges of nanoparticle-based mRNA delivery in cancer treatment.
Karim ME, Haque ST, Al-Busaidi H, Bakhtiar A, et al · · 2022 · cited 31× · PMID 36422795 · DOI 10.1007/s12272-022-01418-x
Development of therapeutic vaccines for the treatment of diseases.
Tian Y, Hu D, Li Y, Yang L. · · 2022 · cited 30× · PMID 36477638 · DOI 10.1186/s43556-022-00098-9
Therapeutic Vaccination for HPV-Mediated Cancers.
Yan F, Cowell LG, Tomkies A, Day AT. · · 2023 · cited 26× · PMID 36743978 · DOI 10.1007/s40136-023-00443-8
Nonviral Delivery Systems of mRNA Vaccines for Cancer Gene Therapy.
Wang Y, Zhang R, Tang L, Yang L. · · 2022 · cited 23× · PMID 35335891 · DOI 10.3390/pharmaceutics14030512

Verify or expand the search:

Other trials of Vvax001 therapeutic cancer vaccine

Trials testing the same drug.

NCT06015854 — Vvax001 Cancer Vaccine in Premalignant Cervical Lesions - Phase II · Phase 2 · unknown

Other recruiting trials for CIN 2/3

Currently open trials in the same condition.

NCT04910802 — Concomitant HPV Vaccination and HPV Screening HPV Infection and Cervical Cancer in Sweden · Phase 4 · recruiting
NCT04098744 — Artesunate Vaginal Inserts for the Treatment of Cervical Intraepithelial Neoplasia (CIN2/3) · Phase 2 · recruiting

Other University Medical Center Groningen trials

Trials by the same sponsor.

NCT06647602 — Thyroid Hormone Replacement After Radio Iodine: Value and Efficacy · not yet recruiting
NCT06809946 — Feasibility of Fluorescence Imaging With Bevacizumab-800CW During Bronchoscopy · Phase 2 · not yet recruiting
NCT07527390 — CANagliflozin In DIALysis Patients · Phase 4 · not yet recruiting
NCT07439237 — Implant-supported Maxillary Overdentures; a 15-years Evaluation · not yet recruiting
NCT07275437 — Effectiveness and Safety of Uptitration of Guideline Directed MEdical Therapy in Heart Failure With Reduced Ejection Fra · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03141463 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Medical Center Groningen
Last refreshed: 3 May 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03141463.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing